Who are Maculaser's investors?

Maculaser's investors include Innovestor Ventures, ZEISS Ventures.

Where is Maculaser headquartered?

Maculaser is headquartered in Helsinki, FI.

Maculaser

Helsinki, FI · Founded 2020 · 5 employees on LinkedIn · 2 known investors

Find your way into Maculaser

Paths you didn't know you had: your email and LinkedIn already hold routes to the Maculaser team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Maculaser develops a temperature-controlled retinal laser therapy to treat age-related macular degeneration, diabetic macular edema, and other retinal disorders by activating natural healing responses in eye cells. The company targets patients and healthcare providers globally for disease prevention and non-invasive retinal care.

Biotech Deep Tech Healthtech Medical Devices

Founders & leadership

Jani TirronenCEOJani Tirronen is CEO of Maculaser, a medical technology company developing laser-based therapy for retinal diseases including age-related macular degeneration. He has over 20 years of experience across multiple industries.

Teemu TurunenChief Scientific Officer, PhD

Ossi KaikkonenHead of ProductOssi Kaikkonen is a biomedical engineer with expertise in machine learning, digital signal processing, optics, and embedded systems design. As Head of Product at Maculaser, he develops a temperature-controlled retinal laser therapy platform to treat age-related macular degeneration and other retinal disorders.

Jaakko NieminenCTO, PhDJaakko Nieminen is CTO of Maculaser, which develops temperature-controlled retinal laser therapy for age-related macular degeneration and related disorders. He has prior research experience in non-invasive brain stimulation and brain imaging at Aalto University, and established the Biodesign Finland MedTech innovation program.

Aki VartiainenClinical Trial Manager

Investors · 2

Innovestor Ventureslisted by Innovestor VenturesHelsinki · $270K – $3.2M

How we know: Innovestor Ventures's portfolio page · innovestorgroup.com · Not right? Tell us

ZEISS Ventureslisted by ZEISS VenturesOberkochen · $550K – $5.5M

How we know: ZEISS Ventures's portfolio page · press coverage · Not right? Tell us

Funding

SEC filings, press & company announcements

Undisclosed amountseed roundSep 2021
Innovestor Ventures (lead)
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Zeiss Backs Maculaser to Fund Retinal Laser Therapy | VMvisionmonday.com · Jun 2026

Frequently asked questions

What does Maculaser do?: Maculaser develops a temperature-controlled retinal laser therapy to treat age-related macular degeneration, diabetic macular edema, and other retinal disorders by activating natural healing responses in eye cells. The company targets patients and healthcare providers globally for disease prevention and non-invasive retinal care.
Who are Maculaser's investors?: Maculaser's investors include Innovestor Ventures, ZEISS Ventures.
Where is Maculaser headquartered?: Maculaser is headquartered in Helsinki, FI.